{
    "organizations": [],
    "uuid": "ade9b44886bf4170b14131ccdc20c305fd191540",
    "author": "",
    "url": "https://www.reuters.com/article/brief-loxo-oncology-completes-rolling-su/brief-loxo-oncology-completes-rolling-submission-of-new-drug-application-to-u-s-food-and-drug-administration-idUSASC09TKA",
    "ord_in_thread": 0,
    "title": "BRIEF-Loxo Oncology Completes Rolling Submission Of New Drug Application To U.S. Food And Drug Administration",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 26, 2018 / 10:55 AM / Updated 20 minutes ago BRIEF-Loxo Oncology Completes Rolling Submission Of New Drug Application To U.S. Food And Drug Administration Reuters Staff 1 Min Read March 26 (Reuters) - Loxo Oncology Inc: * LOXO ONCOLOGY COMPLETES ROLLING SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR LAROTRECTINIB FOR THE TREATMENT OF TRK FUSION CANCER Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)",
    "published": "2018-03-26T13:53:00.000+03:00",
    "crawled": "2018-03-26T14:25:00.025+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "updated",
        "minute",
        "ago",
        "oncology",
        "completes",
        "rolling",
        "submission",
        "new",
        "drug",
        "application",
        "food",
        "drug",
        "administration",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "loxo",
        "oncology",
        "inc",
        "loxo",
        "oncology",
        "completes",
        "rolling",
        "submission",
        "new",
        "drug",
        "application",
        "food",
        "drug",
        "administration",
        "larotrectinib",
        "treatment",
        "trk",
        "fusion",
        "cancer",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}